Axsome slides as traders lock in gains after FDA win, ahead of May 4 earnings
AXSM•Axsome Therapeutics shares fell about 4% on May 1, 2026, after a sharp rally the prior session tied to an FDA label expansion for Auvelity in agitation associated with dementia due to Alzheimer’s disease. The pullback looks driven by profit-taking and positioning ahead of Axsome’s May 4, 2026 Q1 earnings report.
1. What’s moving the stock today
Axsome Therapeutics (AXSM) is down about 3.86% to $200.32 in Friday trading (May 1, 2026), a day after a major regulatory catalyst. The U.S. FDA approved an expanded use for Auvelity to treat agitation associated with dementia due to Alzheimer’s disease in adults on April 30, 2026—an outcome that drove a large one-day move higher into the close. With the binary event now resolved, the stock is giving back a portion of those gains as short-term traders de-risk and lock in profits, while others reposition ahead of the next near-term catalyst: Axsome’s first-quarter 2026 earnings on Monday, May 4, 2026. ()
